Physician profile
John E Donati
NPI 1245308303
$1,467.35
in general payments reported to CMS, 2019-2025
20 companies · $213 in 2025
The $213 reported for 2025 was more than what 75% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $129 · 2021: $195 · 2022: $164 · 2023: $277 · 2024: $334 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $249.77 | 2019-2025 | Doc Band |
| Sanofi Pasteur INC. | $198.76 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $181.23 | 2024-2025 | |
| Kaleo, INC. | $127.93 | 2020-2023 | Auvi-Q |
| Glaxosmithkline, LLC. | $93.70 | 2022-2025 | Bexsero |
| Phadia US INC. | $90.11 | 2024 | Immunocap |
| Pfizer INC. | $83.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $79.86 | 2019-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Cumberland Pharmaceuticals, INC. | $62.58 | 2021-2023 | Kristalose |
| Sobi, INC | $54.24 | 2021-2023 | |
| Genentech USA, INC. | $46.06 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $31.16 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $29.59 | 2021 | |
| Cipher Pharmaceuticals US LLC | $29.44 | 2025 | Spinosad, Natroba |
| Organon LLC | $28.18 | 2025 | Vtama |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $21.43 | 2025 | Neffy |
| Ironwood Pharmaceuticals, INC | $16.72 | 2024 | |
| Aytu Biopharma, INC. | $15.42 | 2021 | |
| Seqirus USA INC | $14.09 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.94 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Donati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.